MX2011007455A - Derivados oxadiazol como agonistas de los receptores de esfingosina-1-fosfato 1 (s1p1). - Google Patents
Derivados oxadiazol como agonistas de los receptores de esfingosina-1-fosfato 1 (s1p1).Info
- Publication number
- MX2011007455A MX2011007455A MX2011007455A MX2011007455A MX2011007455A MX 2011007455 A MX2011007455 A MX 2011007455A MX 2011007455 A MX2011007455 A MX 2011007455A MX 2011007455 A MX2011007455 A MX 2011007455A MX 2011007455 A MX2011007455 A MX 2011007455A
- Authority
- MX
- Mexico
- Prior art keywords
- group
- receptor agonists
- oxadiazole derivatives
- slpl receptor
- nitrogen atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
(ver fórmula (I)) La presente invención se relaciona con nuevos compuestos que tienen la estructura química de la fórmula (I) o las sales farmacéuticamente aceptables o N-óxidos de las mismas, en donde A se selecciona del grupo que consiste de - N-, -O- y -S-; B y C se seleccionan independientemente del grupo que consiste de -N- y -O-, con las condición de que por lo menos dos de A, B y C sean átomos de nitrógeno; G1 se selecciona del grupo que consiste de átomos de nitrógeno y los grupos -CRc-, en donde Rc representa un átomo de hidrógeno, un grupo alquilo C1-4 o un grupo alcoxi C1-4.(ver fórmula (I)).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09382004A EP2210890A1 (en) | 2009-01-19 | 2009-01-19 | Oxadiazole derivatives as S1P1 receptor agonists |
PCT/EP2010/000158 WO2010081692A1 (en) | 2009-01-19 | 2010-01-14 | Oxadiazole derivatives as slpl receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011007455A true MX2011007455A (es) | 2011-08-03 |
Family
ID=40568602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011007455A MX2011007455A (es) | 2009-01-19 | 2010-01-14 | Derivados oxadiazol como agonistas de los receptores de esfingosina-1-fosfato 1 (s1p1). |
Country Status (17)
Country | Link |
---|---|
US (1) | US20110274657A1 (es) |
EP (2) | EP2210890A1 (es) |
JP (1) | JP2012515182A (es) |
KR (1) | KR20110110198A (es) |
CN (1) | CN102282144A (es) |
AR (1) | AR075022A1 (es) |
AU (1) | AU2010205825A1 (es) |
BR (1) | BRPI1005153A2 (es) |
CA (1) | CA2748394A1 (es) |
EA (1) | EA201101089A1 (es) |
EC (1) | ECSP11011200A (es) |
IL (1) | IL213630A0 (es) |
MX (1) | MX2011007455A (es) |
SG (1) | SG172452A1 (es) |
TW (1) | TW201028407A (es) |
UY (1) | UY32364A (es) |
WO (1) | WO2010081692A1 (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2474545T (lt) | 2005-12-13 | 2017-02-27 | Incyte Holdings Corporation | Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai |
LT3070090T (lt) | 2007-06-13 | 2019-06-25 | Incyte Holdings Corporation | Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas |
JP5775070B2 (ja) | 2009-05-22 | 2015-09-09 | インサイト・コーポレイションIncyte Corporation | ヤヌスキナーゼ阻害剤としてのピラゾール−4−イル−ピロロ[2,3−d]ピリミジンおよびピロール−3−イル−ピロロ[2,3−d]ピリミジンのN−(ヘテロ)アリール−ピロリジン誘導体 |
MY161416A (en) | 2009-05-22 | 2017-04-14 | Incyte Holdings Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1h-pyrazol-1-yl]octane-or heptane-nitrile as jak inhibitors |
US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
AR081315A1 (es) | 2010-03-10 | 2012-08-08 | Incyte Corp | Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t |
ME02445B (me) | 2010-05-21 | 2016-09-20 | Incyte Holdings Corp | Topikalna formulacija za inhibiciju jak-a |
EP2635573B1 (en) * | 2010-11-03 | 2014-10-01 | Bristol-Myers Squibb Company | Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases |
AR083933A1 (es) | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
EP2455081A1 (en) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of crohn's disease |
EP2455080A1 (en) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
EP2675451B9 (en) | 2011-02-18 | 2017-07-26 | Novartis Pharma AG | mTOR/JAK INHIBITOR COMBINATION THERAPY |
PE20140832A1 (es) | 2011-06-20 | 2014-07-14 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
JP2014521725A (ja) | 2011-08-10 | 2014-08-28 | ノバルティス・ファルマ・アクチェンゲゼルシャフト | JAKPI3K/mTOR併用療法 |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
WO2013113716A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113788A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113776A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
BR112014018909A8 (pt) | 2012-02-03 | 2017-07-11 | Basf Se | Compostos, processo para a preparação dos compostos, composição agroquímica, método para o combate dos fungos, utilização dos compostos e semente |
WO2013113720A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113773A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
JP2015508752A (ja) | 2012-02-03 | 2015-03-23 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | 殺菌性ピリミジン化合物 |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
CA3178452A1 (en) | 2012-11-15 | 2014-05-22 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
TWI613182B (zh) | 2013-02-21 | 2018-02-01 | 必治妥美雅史谷比公司 | 雙環化合物 |
LT3489239T (lt) | 2013-03-06 | 2022-03-10 | Incyte Holdings Corporation | Jak inhibitoriaus gamybos būdai ir tarpiniai junginiai |
MY195091A (en) | 2013-08-07 | 2023-01-10 | Incyte Corp | Sustained Release Dosage Forms for a JAK1 Inhibitor |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
MA40082B1 (fr) | 2014-08-20 | 2019-09-30 | Bristol Myers Squibb Co | Nouveau compose de substitution sphingosine phosphate utile traitement maladie rhumatisme |
MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
US11192886B2 (en) * | 2016-07-22 | 2021-12-07 | Medshine Discovery Inc. | S1P1 agonist and application thereof |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
WO2019152374A1 (en) | 2018-01-30 | 2019-08-08 | Incyte Corporation | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
MX2020010322A (es) | 2018-03-30 | 2022-11-30 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
CA3158600A1 (en) * | 2019-11-19 | 2021-05-27 | Brian H. Heasley | Compounds and methods of preparing compounds s1p1 modulators |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
KR20230154194A (ko) * | 2021-02-10 | 2023-11-07 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 신장 섬유증의 치료를 위한 HIPK2의 옥사디아졸릴 디하이드로피라노[2,3-b]피리딘 억제제 |
WO2024031041A2 (en) * | 2022-08-05 | 2024-02-08 | Icahn School Of Medicine At Mount Sinai | Oxygen-containing heterocyclic compound and use thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994000943A1 (en) | 1992-06-23 | 1994-01-06 | Motorola, Inc. | Multi-modulation scheme compatible radio |
CA2378713C (en) | 1995-06-21 | 2003-08-12 | Asta Medica Aktiengesellschaft | Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments |
DE10129703A1 (de) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
DE10202940A1 (de) | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
CN1652757B (zh) | 2002-05-16 | 2012-02-08 | 诺瓦提斯公司 | Edg受体结合剂在癌症中的应用 |
GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
AU2004240586A1 (en) * | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists |
EP1484057A1 (en) | 2003-06-06 | 2004-12-08 | Aventis Pharma Deutschland GmbH | Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain |
WO2005025553A2 (en) | 2003-09-12 | 2005-03-24 | Neuronova Ab | Treatment of disorders of nervous systemsystem with fty720 |
CA2539438A1 (en) * | 2003-10-01 | 2005-04-14 | Merck And Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
EP1697333A4 (en) * | 2003-12-17 | 2009-07-08 | Merck & Co Inc | 3,4-DISUSBSTITUTED PROPANOIC CARBOXYLATES AS S1P RECEPTOR AGONISTS (EDG) |
GB0329498D0 (en) | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
BRPI0612028A2 (pt) * | 2005-06-08 | 2010-10-13 | Novartis Ag | oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p |
GB0601744D0 (en) * | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
KR20080086546A (ko) | 2006-01-27 | 2008-09-25 | 유니버시티 오브 버지니아 페이턴트 파운데이션 | 신경병증성 통증의 치료 방법 |
TWI389683B (zh) | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
WO2007143081A2 (en) | 2006-06-02 | 2007-12-13 | The Ohio State University Research Foundation | Therapeutic agents for the treatment of lymphoid malignancies |
GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
WO2008021532A2 (en) | 2006-08-17 | 2008-02-21 | University Of Chicago | Treatment of inflammatory diseases |
-
2009
- 2009-01-19 EP EP09382004A patent/EP2210890A1/en not_active Withdrawn
- 2009-12-23 UY UY0001032364A patent/UY32364A/es not_active Application Discontinuation
-
2010
- 2010-01-13 TW TW099100840A patent/TW201028407A/zh unknown
- 2010-01-14 SG SG2011048329A patent/SG172452A1/en unknown
- 2010-01-14 WO PCT/EP2010/000158 patent/WO2010081692A1/en active Application Filing
- 2010-01-14 CN CN2010800049696A patent/CN102282144A/zh active Pending
- 2010-01-14 EP EP10700383A patent/EP2387571A1/en not_active Withdrawn
- 2010-01-14 AU AU2010205825A patent/AU2010205825A1/en not_active Abandoned
- 2010-01-14 JP JP2011545678A patent/JP2012515182A/ja active Pending
- 2010-01-14 EA EA201101089A patent/EA201101089A1/ru unknown
- 2010-01-14 MX MX2011007455A patent/MX2011007455A/es not_active Application Discontinuation
- 2010-01-14 US US13/144,377 patent/US20110274657A1/en not_active Abandoned
- 2010-01-14 BR BRPI1005153A patent/BRPI1005153A2/pt not_active IP Right Cessation
- 2010-01-14 CA CA2748394A patent/CA2748394A1/en not_active Abandoned
- 2010-01-14 KR KR1020117016785A patent/KR20110110198A/ko not_active Application Discontinuation
- 2010-01-15 AR ARP100100089A patent/AR075022A1/es unknown
-
2011
- 2011-06-16 IL IL213630A patent/IL213630A0/en unknown
- 2011-07-13 EC EC2011011200A patent/ECSP11011200A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2010205825A1 (en) | 2011-07-07 |
CN102282144A (zh) | 2011-12-14 |
EA201101089A1 (ru) | 2012-02-28 |
KR20110110198A (ko) | 2011-10-06 |
CA2748394A1 (en) | 2010-07-22 |
TW201028407A (en) | 2010-08-01 |
EP2387571A1 (en) | 2011-11-23 |
WO2010081692A1 (en) | 2010-07-22 |
IL213630A0 (en) | 2011-07-31 |
BRPI1005153A2 (pt) | 2019-09-24 |
UY32364A (es) | 2010-02-26 |
EP2210890A1 (en) | 2010-07-28 |
SG172452A1 (en) | 2011-07-28 |
JP2012515182A (ja) | 2012-07-05 |
ECSP11011200A (es) | 2011-08-31 |
AR075022A1 (es) | 2011-03-02 |
US20110274657A1 (en) | 2011-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011007455A (es) | Derivados oxadiazol como agonistas de los receptores de esfingosina-1-fosfato 1 (s1p1). | |
MX2009004920A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1. | |
EP2597088A4 (en) | P2X4 Receptor Antagonists | |
MY153393A (en) | Amino nicotinic and isonicotinic acid derivatives as dhodh as inhibitors | |
UA95972C2 (ru) | Аминопиридиновые производные с селективной ингибирующей активностью в отношении авроры а | |
MX2009012283A (es) | Derivado heterociclico que contiene nitrogeno que tiene actividad inhibitoria de 11beta-hidroxiesteroide-deshidrogenasa tipo 1. | |
UA109525C2 (xx) | Алкіламідна сполука і її застосування | |
GB0505048D0 (en) | Compounds with PGD antagonist activity | |
RS53451B (en) | INHIBITORI P70 S6 KINAZE | |
TW200833675A (en) | Nicotinamide derivatives | |
WO2008087611A3 (en) | Pyrrolidine- and piperidine- bis-amide derivatives | |
WO2008108378A3 (en) | Bicyclic oxomorpholine derivative | |
JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
IL180171A0 (en) | Novel 2-substituted d-homo-estra-1,3,5(10)-trienes as inhibitors of 17??- hydroxysteroid dehydrogenase type 1 | |
MX2009011769A (es) | Derivados de piridona como inhibidores de mapk p38a. | |
MX2009007260A (es) | Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5). | |
EA201100612A1 (ru) | Новые производные 2-амидотиадиазола | |
MY149400A (en) | Bridged six-membered ring compounds | |
MX360667B (es) | Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5). | |
WO2012103071A3 (en) | Compounds and compositions | |
MX337443B (es) | Derivados de etinilo como moduladores alostericos positivos del receptor de glutamato metabotropico del subtipo 5 (mglur5). | |
MX353190B (es) | Derivados de isoquinolina y naftiridina. | |
MX2013007938A (es) | Compuesto biciclico novedoso o sal del mismo. | |
CL2010001639A1 (es) | Proceso para preparacion del hemitartrato de [5-(4,6-dimetil-1h-benzoimidazol-2-il-metil-pirimidin-2-il]-[3-(metil-piperidin-4-il)propil]amina; proceso de recristalizacion del hemitartrato; y hemitaatrato cristalino de [5-(4,6-dimetil-1h-benzoimidazol-2-il)-4-metil- pirimidin-2-il]-[3-(1-metil-piperidin-4-il)-propil]-amina. | |
IN2012DN00770A (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |